Further information has been obtained from clinical trials of vaccines developed by Pfizer and Bioentech to prevent coronavirus (Covid-19). According to the latest data, the two companies claim that the vaccine is 95 per cent effective. Of these, the vaccine is 94 per cent effective in people aged 65 and over, they said.
According to the BBC, of the volunteers who received the vaccine, analyzing the data of 160 people, it was found that 95 per cent of them were effective. No significant side effects were observed in them. Earlier, after analyzing the data of 94 volunteers, Pfizer said their vaccine was 90 per cent effective.
Pfizer and Biotech’s statement
Pfizer and Bioentech say the findings are promising. This time they will apply for permission to administer the vaccine as a matter of urgency. Pfizer thinks they will be able to produce more than 50 million doses of the vaccine by the end of this year. They are optimistic about 1.3 billion doses by 2021. However, there are also challenges in preserving this vaccine. The vaccine should be stored at a temperature of minus 60 degrees Celsius.
Scientists say the findings from Pfizer and Bioentech vaccine analysis are promising. This development is significant, said Oxford University, Professor Trudy Lank. This breakthrough in the experimental phase of several vaccines so quickly after the detection of a new virus is an outstanding milestone for science.
Clinical trials of the vaccine
Although the clinical trial of Pfizer’s corona vaccine has not yet been completed, the company says its findings do not pose a security risk. However, 2% of the volunteers who received the vaccine had symptoms such as headache and fatigue. However, in the case of the elderly, the effect was minimal.